---
schema_version: "secwatch.filing_event.v1"
accession: "0001021771-24-000140"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:40:54.725868+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioRestorative Therapies restates financials due to warrant classification error; no cash impact

## Summary
- Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.
- Restatement reclassifies 2,645,000 public warrants ($10 exercise), 1,856,938 private warrants ($10), and 235,970 underwriter warrants ($12.50) from equity to liabilities.
- Non-cash adjustments affect balance sheet and fair value changes in operations; no impact on cash, revenue, operating expenses, or loss from operations.
- Company plans to file amended 10-K by June 28, 2024, and concurrently file Q1 2024 10-Q.
- Audit committee discussed matter with independent auditor Marcum LLP.

## SEC filing metadata
- accession: 0001021771-24-000140
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000140/0001021771-24-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000140/brt8k523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001021771-24-000140
- JSON: https://secwatch.observer/filing/0001021771-24-000140.json
- Plain text: https://secwatch.observer/filing/0001021771-24-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.